Tumor Immune Contexture Is a Determinant of Anti-CD19 CAR T Cell Efficacy in Large B Cell Lymphoma

Researchers assessed whether tumor immune contexture influenced clinical outcomes after axicabtagene ciloleucel. They evaluated the tumor microenvironment of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 Phase II trial.